Abraxis BioScience LLC, part of Bristol Myers Squibb Co., is a company headquartered in Los Angeles, CA, involved in commercial physical and biological research.

Manufactures pharmaceuticals

Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is an American company located in Norwood, MA. The firm develops anticancer drugs. It was founded by Chiang J. Li. On April 25, 2012 Sumitomo Pharma Co., Ltd. acquired Boston Biomedical, Inc. for $2,630 million.\nThe company says this about itself: Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Boston Biomedical works closely with its parent company, Sumitomo Dainippon Pharma, and Tolero Pharmaceuticals, also a wholly owned subsidiary, to advance a pipeline of innovative oncology treatments. The organizations apply their expertise and collaborate to achieve a common objective – expediting the discovery, development and commercialization of novel treatment options.

Caris Molecular Profiling Institute, Inc. provides research and laboratory testing services. It offers tests to help oncologists to understand and treat cancer patients with personalized treatment plans based on the molecular characteristics of their tumors. The company offers services to the hospitals, physicians, and clinical research sponsors. Caris Molecular Profiling Institute was founded on 1996 and is headquartered in Phoenix, AZ.

Yakult Honsha Co., Ltd. engages in the manufacture and sale of food and beverage products, cosmetics, and pharmaceuticals. It operates through the following segments: Food and Beverages in Japan, the Americas, Asia and Oceania, and Europe; Pharmaceuticals, and Others. The Food and Beverages segment produces and merchandises milk drinks, noodles, juices, and soft drinks. The Pharmaceuticals segment manufactures and sells anti-cancer drugs and other pharmaceutical products. The Others segment includes cosmetics and professional baseball team management. The company was founded by Minoru Shirota in 1935 and is headquartered in Tokyo, Japan.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

Personal Oncology specializes in the diagnosis and treatment of tumors. It has developed a PDTX technology (FASTPDTX) that has reached the clinical use level.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

NovoCure GmbH, a subsidiary of NovoCure Ltd., is a company headquartered in Munich, Germany, that develops proprietary therapy. Wilhelmus C. M. Groenhuysen and Asaf Danziger are the current co-CEOs of the firm.

Asahi Kasei Pharma Corp., a subsidiary of Asahi Kasei Corp., is a company headquartered in Tokyo, Japan, that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

Sumitomo Dainippon Pharma Oncology, Inc., part of Sumitomo Chemical Co., Ltd., is an American company located in Cambridge, MA, that develops novel cancer therapeutics. Patricia S. Andrews is currently the CEO of the firm.\nThe company says this about itself: Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. SDP Oncology's robust and diverse pipeline of preclinical and advanced-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.

Carbon Logic Biotechnology (Foshan) Co., Ltd., established on 2018-06-21, Business scope includes general items:Development of Human Gene Diagnosis and Therapy Technology;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug Clinical Trial Services;Inspection and testing service;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Shenzhen Zheyuan Biotechnology Co., Ltd., established on 2019-10-18, Business scope includes general business items:engaged in medical technology,Biological Technology,information technology field,computer network technology field,Technology development in the field of electronic technology,Technology Promotion,technical consulting,Technical Services,technology transfer;Computer system and basic application software services;Engineering and Technology Research and Experimental Development;Health and wellness management consulting(Does not contain medical behavior);Research and development of scientific reagents;gene related technology,genetic testing technology,gene chip,Research on Biopharmaceutical Products,to develop;Biological product technology development;Domestic Trade;Operating import and export business(above according to the law,Administrative regulations,Decisions of the State Council and other regulations that require approval,Can only operate after obtaining relevant approval documents according to law),The licensing program is:IIkind,IIIThree categories6840Production of in vitro diagnostic reagents;one type,Class II,Sales of Class III Medical Devices;Class II,Sales of three types of in vitro diagnostic reagents;Western medicine retail.

Zhejiang Free Trade Zone Ruisai Biomedical Technology Co., Ltd., established on 2018-06-06, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;Engineering and Technology Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Import and export agency;R&D and application of cell technology;Human stem cell technology development and application(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Shanghai Yangpu District Central Hospital is a Chinese private company located in Shanghai. The firm provides general medical and surgical hospital services.